Unveiling Details, Unlocking Hope
Comprehensive Genomic & Transcriptomic Profiling with Ultra-sensitive ctDNA-MRD Monitoring
DNA
Precision oncology decision support (PODS) for personalized cancer therapy
RNA
Surveillance for Cancer Recurrence and Assessment of Treatment Efficacy
ctDNA-MRD Monitoring
Personalized 10 mutations, Fixed panel of 700 hotspots, Viral DNA with AI-enhanced
Advancing Precision Cancer Treatment: Expanding Opportunities
Precision medicine employs personalized treatment strategies informed by comprehensive genetic testing and the specific cancer type. This approach aims to assess the patient's potential response to therapies.
By strategically combining targeted therapy, immunotherapy, and traditional chemotherapy within a treatment plan tailored to the molecular profile of the patient's tumor, precision medicine endeavors to enhance survival outcomes for cancer patients.
Transforming Cancer Care: Breakthroughs in Personalized Treatment and Cancer Tracking
The K-4CARE test is a comprehensive genomic profiling assay designed to generate a detailed molecular profile of solid tumors. The scope of testing is recommended by the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and U.S. Food and Drug Administration (FDA).
By analyzing a broad range of clinically relevant alterations, K-4CARE empowers clinicians to identify the most targetable mutations within each patient's tumor. This information guides the selection of personalized treatment strategies, including targeted therapies and immunotherapies. Additionally, K-4CARE facilitates the monitoring of treatment response, assesses the emergence of drug resistance, and enables vigilant surveillance for early signs of cancer recurrence.
Benefits of Comprehensive genomic profiling
1. Three comprehensive markers for immunotherapy response: PD-L1, TMB, MSI-NGS
473 genes for all solid tumors
2. Somatic mutations for targeted therapy &identification of drug resistance mechanisms
Lastest targeted therapy for all solid tissue tumors
3. Germline mutations are associated with treatment reponse, prognosis & genetic risk assessment for the patient's family
Most common types of heredity cancers
4. Personalized cancer tracking to detect minimal residual disease, monitor treatment response and detect early recurrence
Applied free of charge for cancers fits with MRD
5. Tumor Tissue of Origin for CUP
Identify the tumor tissue of origin for Cancer of Unknown Primary (CUP) to enable site-specific therapy
6. Oncovirus Profile (Viral DNA)
Detect viral DNA (HPV, EBV, HBV) linked to selected cancers, which can influence diagnosis, prognosis, and treatment choices
Why K-4CARE
Comprehensive 473-Gene Panel for Solid Tumor Profiling
Comprehensive Biomarker Profiling to Optimize Treatment Selection, Including Targeted Therapy and Immunotherapy.
Empowering Informed Treatment Decision-Making for Doctors and Patients
Comprehensive molecular tumor profiling provides valuable insights. This information facilitates proactive collaboration between clinicians and patients, enabling the selection of the most appropriate treatment strategy.
Save Time + Cost + Precious tissue samples
This comprehensive tumor analysis requires a single test, preserving valuable tissue samples and reducing costs. It provides extensive molecular insights, empowering clinicians to proactively adapt treatment plans based on early indicators of drug resistance, treatment non-response, or disease progression.
Post-Treatment Surveillance and Recurrence Monitoring: Accompanying the Patient
Sample collection
Tissue sample
Block FFPE/FFPE tumor tissue slices
